Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

This trial tests a new tablet drug called XNW5004 combined with pembrolizumab (a standard immunotherapy) in people with advanced solid tumors — including head and neck cancer, bladder cancer, prostate cancer, lung cancer, and others — whose cancer has stopped responding to prior standard treatments including immunotherapy. **You may be eligible if...** - You are 18 or older with an advanced solid tumor from the eligible cancer types (e.g., head/neck cancer, bladder cancer, NSCLC, SCLC, prostate cancer, or others) - Your cancer has progressed after prior standard therapy, including PD-1/PD-L1 immunotherapy for most cohorts - You have adequate organ function and measurable disease **You may NOT be eligible if...** - You have uncontrolled brain metastases - You have active autoimmune disease requiring systemic treatment - You are pregnant or breastfeeding - You have had a recent serious cardiovascular event - You have active hepatitis B or C or uncontrolled HIV Talk to your doctor to see if this trial is right for you.